This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Chelsea Therapeutics International, Ltd.

Rigrodsky & Long, P.A. announces that a complaint has been filed in the United States District Court for the Western District of North Carolina, Charlotte Division on behalf of all persons or entities that purchased the securities of Chelsea Therapeutics International, Ltd. (“Chelsea” or the “Company”) (NasdaqCM: CHTP) between June 9, 2011 and February 17, 2012, inclusive (the “Class Period”), alleging violations of the Securities Exchange Act of 1934 against the Company and certain of its officers and directors (the “Complaint”).

If you purchased shares of Chelsea during the Class Period, or purchased shares prior to the Class Period and still hold Chelsea stock, and wish to discuss this action or have any questions concerning this notice or your rights or interests, please contact Timothy J. MacFall, Esquire or Scott J. Farrell, Esquire of Rigrodsky & Long, P.A., 825 East Gate Boulevard, Suite 300, Garden City, NY at (888) 969-4242, by e-mail to, or at:

Chelsea, a Delaware corporation headquartered in Charlotte, North Carolina, is a biopharmaceutical company whose lead investigational drug was Northera (trade name Droxidopa) (“Droxidopa”). Droxidopa was in development for treatment of neurogenic orthostatic hypotension (“NOH”) in people with primary autonomic failure, including Parkinson’s disease. Droxidopa has been approved for use in Japan since 1989, but is marketed at lower doses. The Complaint alleges that throughout the Class Period, defendants made materially false and misleading statements regarding the safety and efficacy of Droxidopa, which was then in Phase III testing. Specifically, the Complaint alleges that despite defendants’ positive statements, they failed to disclose that the safety data base was small in light of red flags concerning the safety of Droxidopa that arose during the open-label phases of the trial, including 18 deaths from sepsis, heart attack, pneumonia, respiratory failure, myocardial infarctions, progression of the underlying disease and hyperextensive crisis. In addition, the Complaint alleges there were nine cases of life-threatening neuroleptic malignant syndrome over a ten-year period in Japan; and there were no durable effects from the drug that lasted more than four weeks, which did not warrant approval by the U.S. Food and Drug Administration (the “FDA”) in light of the safety issues with the drug.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.64 -0.11%
FB $118.57 0.84%
GOOG $698.21 0.75%
TSLA $241.80 0.43%
YHOO $36.53 -0.19%


Chart of I:DJI
DOW 17,891.16 +117.52 0.66%
S&P 500 2,081.43 +16.13 0.78%
NASDAQ 4,817.5940 +42.2360 0.88%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs